NCT05222165: Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 3 Years and older (Child, Adult, Older Adult))
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with prior treatment of a FGFR1-3 selective inhibitor

Comments are closed.

Up ↑